Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC)

NCT05546411 is registered in ClinicalTrials.gov with Kimberly Perez, MD as lead sponsor.

NCT NCT05546411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05546411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC)
Lead sponsor
Kimberly Perez, MD
Phase
Phase 2
Overall status
Terminated
Start date
January 6, 2023
Completion date
October 13, 2023
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic adenocarcinoma, pancreatic adenocarcinoma, pancreatic cancer, resectable pancreatic cancer